Emergent BioSolutions Inc. (EBS): M&A transaction — Emergent BioSolutions closes sale of travel health business to Bavarian Nordic for $270M upfront

Emergent BioSolutions Inc.

Emergent closed sale of travel health business to Bavarian Nordic on May 15, 2023 for $270M upfront cash.
Potential milestone payments: up to $80M for CHIKV VLP development/approval and $30M earnout on 2026 net sales.
Assets sold include typhoid vaccine Vivotif, cholera vaccine Vaxchora, CHIKV VLP candidate, Bern manufacturing site, San Diego development facilities.
Majority of employees supporting these products and facilities are joining Bavarian Nordic.

item 2.01 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Emergent BioSolutions Inc. completed a disposition involving Bavarian Nordic for $270 million (closed 2023-05-15).

Action: disposition
Counterparty: Bavarian Nordic
Consideration: $270 million
Closing: 2023-05-15

Exact text from the filing

the Company’s manufacturing site in Bern, Switzerland; and certain of its development facilities in San Diego, California. At the closing, Buyer paid a cash purchase price of $270 million, exclusive of customary closing adjustments for cash, indebtedness, working capital and transaction expenses of the business at closing (the "Purchase Price"). Bavarian Nordic

View on SEC.gov

Browse all m&a transactions →

Emergent BioSolutions Inc. filing history →

Source: SEC EDGAR

accession 0001367644-23-000091

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.